US Patent
US8617600 — Modified release preparations containing oxcarbazepine and derivatives thereof
Formulation · Assigned to Supernus Pharmaceuticals Inc · Expires 2027-04-13 · 1y remaining
Vulnerability score
65/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects controlled-release preparations of oxcarbazepine and its derivatives for once-a-day administration with tailored release profiles.
USPTO Abstract
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.